Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 13/20 | 0.53 |
| ▸ | HTR2A | P28223 | 11/20 | 0.53 |
| ▸ | DRD2 | P14416 | 11/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579575 | 0.82 | DRD4 (0.59) | CHRM4DRD4HTR2ADRD2MCHR1 | |
| SCHEMBL5165935 | 0.81 | HDAC1 (0.63) | CHRM4DRD4DRD2MCHR1LTA4H | |
| SCHEMBL4580616 | 0.80 | HDAC1 (0.63) | HDAC1 | |
| SCHEMBL4788938 | 0.80 | HDAC1 (0.52) | CHRM4DRD4HTR2ADRD2MCHR1 | |
| SCHEMBL4578742 | 0.80 | HDAC1 (0.63) | HDAC1 | |
| SCHEMBL4578738 | 0.80 | HDAC1 (0.63) | HDAC1 | |
| SCHEMBL5188483 | 0.79 | LSS (0.52) | CHRM4LTA4HPDE2AJAK2HDAC1 | |
| SCHEMBL5191116 | 0.79 | LSS (0.52) | CHRM4LTA4HPDE2AJAK2HDAC1 | |
| SCHEMBL8231625 | 0.79 | HDAC1 (0.49) | DRD4HTR2AHDAC1 | |
| SCHEMBL4579564 | 0.79 | HDAC1 (0.64) | CHRM4DRD4HTR2ADRD2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | claimed |
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014733-A1 | Histamine-3 agonists and antagonists | HRH3, HRH4, HRH2 | CHRM4 209/4885DRD4 330/4885HTR2A 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.